LianBio Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LianBio share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was 36.55K shares.
- LianBio share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.00M shares, a 25.73% decline from fiscal 2021.
- LianBio share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 1.35M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2022-12-31 | 1.00M shares 10-K · filed 2023-03-28 | |
| 2021-12-31 | 36.55K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | 1.35M shares 10-K · filed 2022-03-31 |